We are pleased to announce a further £300,000 investment from leading charity Kidney Research UK into Kidney Beam, with the aim of helping thousands more people living with kidney disease and closely-related risk factors access exercise, education, dietary and coaching support from the comfort of their own homes.
The investment follows our landmark clinical trial and several research studies highlighting the positive impacts driven by digital kidney rehabilitation programmes, plus the launch of our new NHS-commissioned service in North Central London.
Kidney Beam’s ultimate ambition is to make these services available to everyone living with kidney disease, while strengthening support for people with closely interconnected cardiovascular, kidney and metabolic (CVKM) conditions, including diabetes, heart disease and high blood pressure.
These conditions frequently occur together with kidney disease, sharing common risk factors and often accelerating one another's progression. By addressing them together through exercise, lifestyle support and personalised coaching, we aim to help people manage their health more effectively and improve their long-term wellbeing.
The expansion also reflects a growing focus within the NHS on preventing long-term conditions from developing or worsening, rather than waiting until people need more intensive treatment. Supporting people with interconnected CVKM conditions earlier could help reduce the risk of disease progression, cardiovascular complications and the need for more costly interventions.
Investing in the next phase of growth
Kidney Research UK's commitment represents half of a new £600,000 investment round, with Kidney Beam seeking the remaining funding from existing and new investors.
The investment will support three key priorities:
Expanding access: Strengthening capabilities to establish new NHS and healthcare partnerships, while deepening support to people with closely-associated cardiovascular and metabolic conditions.
Growing operations: Support the successful delivery and expansion of CVKM-specific services, helping more patients benefit from specialist rehabilitation
Investing in innovation: Researching how AI-assisted technology can enhance patient engagement and support more people cost-effectively.
Lucy Sreeves, chief income and engagement officer for Kidney Research UK said: "Helping people with kidney disease stay active and manage their health can make a real difference to their quality of life, yet too many people still lack access to specialist support.
"Our further investment reflects our confidence in Kidney Beam's next phase of development and its potential to reach many more people and make a lasting difference to kidney care."
Professor Sharlene Greenwood, co-founder and chief medical officer at Kidney Beam said: "We've demonstrated that our approach works for people living with kidney disease, and our focus now is on making that support available to as many people as possible.
"Kidney disease is closely connected to other conditions, including diabetes, high blood pressure and cardiovascular disease. We see a significant opportunity to build on our expertise in kidney rehabilitation to support people living with these interconnected conditions, helping them take greater control of their health and potentially preventing more serious complications.
"With further partnerships in development, we're excited about the opportunity to reach many more people and make a lasting difference to their health and wellbeing."
If you’re an investor interested in learning more about investing in this round alongside Kidney Research UK, please email investor-relations@kidneybeam.com by November 10th 2026 at the latest